The genotype- and sex-dependent effect of SP-A on NAD(H) redox status and oxidative stress/inflammatory pathways may be of clinical relevance in COVID-19 patients and SP-A may be considered as a potential therapy. The gene discussed is SFTPA1; the disease is COVID-19.